A photo of Min Dong.

Min Dong, PhD


  • Assistant Professor, UC Department of Pediatrics

About

Biography

I am a researcher in the field of clinical pharmacology, and I came to Cincinnati Children’s in 2011. My areas of interest include pediatric pharmacokinetic/pharmacodynamic (PK-PD) modeling and simulation, individualized Bayesian dose optimization and clinical trial design.

My research goals are to use novel quantitative approaches to facilitate drug development and dose optimization for drugs such as antibiotics, immunosuppressants and cancer drugs in pediatric patients.

I have worked with my colleagues at Cincinnati Children’s, Drs. Patrick McGann and Russell Ware in the Division of Hematology and Dr. Alexander Vinks in the Division of Clinical Pharmacology, to develop a PK-guided Bayesian adaptive control algorithm to individualize the hydroxyurea dose in patients with sickle cell disease (SCD).

We recently reported the results of a prospective clinical trial (TREAT study: ClinicalTrials.gov NCT02286154) indicating that this PK-guided dosing approach is able to predict a safe starting dose of hydroxyurea. This can significantly reduce the time interval for patients to reach their personal maximum tolerated dose (MTD).

Our collaboration on sickle cell disease has also thrived with other research efforts. These include international studies performed in the Caribbean (EXTEND: NCT02556099) and in sub-Saharan Africa (REACH: NCT01966731 and NOHARM: NCT01976416), as well as studying hydroxyurea exposure in lactation (HELPS study).

Publications

Selected

Model-informed precision dosing for alemtuzumab in paediatric and young adult patients undergoing allogeneic haematopoietic cell transplantation. Dong, M; Emoto, C; Fukuda, T; Arnold, DE; Mehta, PA; Marsh, RA; Vinks, AA. British Journal of Clinical Pharmacology. 2021.

Selected

Changing the Clinical Paradigm of Hydroxyurea Treatment for Sickle Cell Anemia Through Precision Medicine. Dong, M; McGann, PT. Clinical Pharmacology and Therapeutics. 2021; 109:73-81.

Selected

Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia. McGann, PT; Niss, O; Dong, M; Marahatta, A; Howard, TA; Mizuno, T; Lane, A; Kalfa, TA; Malik, P; Quinn, CT; et al. American Journal of Hematology. 2019; 94:871-879.

Selected

Model-based dosing with concentration feedback as an integral part of personalized hydroxycarbamide management. Dong, M; McGann, PT; Mizuno, T; Ware, RE; Vinks, AA. British Journal of Clinical Pharmacology. 2018; 84:1410-1412.

Selected

Population Pharmacokinetics and Optimal Sampling Strategy for Model-Based Precision Dosing of Melphalan in Patients Undergoing Hematopoietic Stem Cell Transplantation. Mizuno, K; Dong, M; Fukuda, T; Chandra, S; Mehta, PA; McConnell, S; Anaissie, EJ; Vinks, AA. Clinical Pharmacokinetics. 2018; 57:625-636.

Selected

Clinical Trial Simulations and Pharmacometric Analysis in Pediatrics: Application to Inhaled Loxapine in Children and Adolescents. Dong, M; Fukuda, T; Selim, S; Smith, MA; Rabinovich-Guilatt, L; Cassella, JV; Vinks, AA. Clinical Pharmacokinetics. 2017; 56:1207-1217.

Selected

Urinary kidney injury biomarkers and tobramycin clearance among children and young adults with cystic fibrosis: a population pharmacokinetic analysis. Downes, KJ; Dong, M; Fukuda, T; Clancy, JP; Haffner, C; Bennett, MR; Vinks, AA; Goldstein, SL. Journal of Antimicrobial Chemotherapy. 2017; 72:254-260.

Selected

Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia. Dong, M; McGann, PT; Mizuno, T; Ware, RE; Vinks, AA. British Journal of Clinical Pharmacology. 2016; 81:742-752.

Selected

Propofol Pharmacokinetics and Estimation of Fetal Propofol Exposure during Mid-Gestational Fetal Surgery: A Maternal-Fetal Sheep Model. Ngamprasertwong, P; Dong, M; Niu, J; Venkatasubramanian, R; Vinks, AA; Sadhasivam, S. PLoS ONE. 2016; 11.

Selected

Population pharmacokinetic-pharmacodynamic modelling of mycophenolic acid in paediatric renal transplant recipients in the early post-transplant period. Dong, M; Fukuda, T; Cox, S; de Vries, MT; Hooper, DK; Goebel, J; Vinks, AA. British Journal of Clinical Pharmacology. 2014; 78:1102-1112.